Clinical trials
Phase 2/3 Parkinson Disease trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
53 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2003 | 1 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 2 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 29 |
| Recruiting | 7 |
| Unknown status | 7 |
| Terminated | 5 |
| Withdrawn | 5 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Tanta University | 3 |
| Addex Pharma S.A. | 2 |
| Fudan University | 2 |
| Otsuka Pharmaceutical Co., Ltd. | 2 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 2 |
| University of Calgary | 2 |
| Adamas Pharmaceuticals, Inc. | 1 |
| Alessandra Tanuri Magalhães | 1 |
| Annovis Bio Inc. | 1 |
| Avid Radiopharmaceuticals | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Parkinson Disease | 53 |
| Dyskinesias | 3 |
| Dyskinesia, Drug-Induced | 2 |
| Parkinsonian Disorders | 2 |
| REM Sleep Behavior Disorder | 2 |
| Alzheimer Disease | 1 |
| Deglutition Disorders | 1 |
| Dementia | 1 |
| Disorders of Excessive Somnolence | 1 |
| Dystonia | 1 |
Trials
Showing 26 to 50 of 53. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.